Advanced Urology Acquires Three ExactVu™ Micro-Ultrasound Systems to Provide State-of-the-Art Real-Time Targeted Prostate Biopsies Across Atlanta
Advanced Urology has acquired three ExactVu™ micro-ultrasound systems with FusionVu capabilities reports Exact Imaging.
Vascular Insights’ primary assets are the ClariVein®IC and ClariVein®OC specialty infusion and occlusion catheter systems.
11/20/18: The transaction has been unanimously approved by the boards of directors of Boston Scientific and BTG. Under the terms of the transaction, holders of BTG's common shares would receive cash consideration of 840 pence per share. The total cash consideration for 100% of BTG's equity is approximately £3.3B, or U.S.$4.2B. The transaction is intended to be effected by way of an English court-sanctioned scheme of arrangement, and is expected to close in the first half of 2019, subject to receipt of required regulatory approvals and the approval of BTG's shareholders and the U.K. court.
MED Medical Products is a specialist producer of customized procedure packs and disposable products used in ophthalmic surgery based in Karlstein, Germany, and was founded in 1997.
Acquisition adds the most advanced dermoscopy R&D Team to Canfield's medical dermatology solutions, significantly expands European presence
Johnson & Johnson Medical GmbH Acquires Emerging Implant Technologies GmbH to Enhance Global Offering of Interbody Spine Implants
The acquisition of Emerging Implant Technologies GmbH allows DePuy Synthes, the orthopaedics business of Johnson & Johnson, to enhance its comprehensive interbody implant portfolio that includes expandable interbody devices, titanium integrated PEEK technology and now 3D-printed cellular titanium, for both minimally invasive and open spinal surgery.
With Precedent Health, SpecialtyCare increases the number of associates available to support cases in our existing markets across the United States while adding significant new coverage in markets such as Buffalo NY; New York City, NY; Detroit, MI; and Portland, OR.
"The proprietary technologies and core competencies of each company are perfectly synergistic. Blending them enhances and accelerates the delivery of our products to health care practitioners, researchers, and pharmaceutical companies seeking to more precisely assess and monitor immune status dynamics. The addition of Biosensia's EU-based ISO-certified facilities and deeply experienced core team allows us to bring product development, quality control and test manufacturing in house and continue to provide contract assay development and manufacturing services to Biosensia clients around the world," according to Chad Stiening, Ph.D., Chief Executive Officer, Kypha.